GlassScriptPhysician profile
Alka Aggarwal
NPI 1467731950
$3,829.53
in general payments reported to CMS, 2019-2025
32 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $425 · 2021: $529 · 2022: $722 · 2023: $894 · 2024: $412 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $682.77 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $415.92 | 2021-2025 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $401.13 | 2020-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $300.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $244.33 | 2019-2025 | |
| Amgen INC. | $187.93 | 2020-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $183.38 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $171.47 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $155.04 | 2019-2022 | |
| Glaxosmithkline, LLC. | $132.96 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $129.19 | 2022 | |
| Merck Sharp & Dohme LLC | $117.70 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $90.53 | 2019-2021 | |
| Aadi Bioscience, INC. | $87.87 | 2024 | Fyarro |
| Novartis Pharmaceuticals Corporation | $75.64 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $60.22 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $54.54 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $52.83 | 2023 | Gemtesa |
| Shield Therapeutics INC | $33.19 | 2025 | |
| Vivus LLC | $27.76 | 2022-2023 | Qsymia |
| Idorsia Pharmaceuticals US INC | $27.17 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $25.61 | 2019-2020 | |
| Smith+Nephew, INC. | $24.84 | 2023 | Collagenase Santyl |
| Phadia US INC. | $21.99 | 2024 | Immunocap |
| Corcept Therapeutics | $20.24 | 2025 | Korlym |
| Janssen Biotech, INC. | $19.97 | 2019 | |
| Allergan, INC. | $16.76 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.15 | 2023 | Jardiance |
| Bausch Health US, LLC | $14.49 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.66 | 2023 | Qelbree |
| Tolmar, INC. | $12.80 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.